Intestinal metaplasia in Barrett's oesophagus: An essential factor to predict the risk of dysplasia and cancer development

Digestive and Liver Disease

Volumn 48, Issue 2, 2016, Pages 144-147

  Salemme, Marianna ^a   Villanacci, Vincenzo ^a   Cengia, Gianpaolo ^b   Cestari, Renzo ^b   Missale, Guido ^b   Bassotti, Gabrio ^c  

^a SPEDALI CIVILI   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Barrett's oesophagus; Cancer development; Endoscopy; Intestinal metaplasia

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CHILD; DISEASE COURSE; ESOPHAGUS CANCER; ESOPHAGUS DYSPLASIA; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; ADENOCARCINOMA; CASE CONTROL STUDY; ESOPHAGEAL NEOPLASMS; FOLLOW UP; METAPLASIA; MIDDLE AGED; PATHOLOGY; PRECANCEROUS CONDITIONS; PRESCHOOL CHILD; RISK; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METAPLASIA; MIDDLE AGED; PRECANCEROUS CONDITIONS; RETROSPECTIVE STUDIES; RISK; YOUNG ADULT;

EID: 84957845702     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2015.10.021     Document Type: Article

References (19)

1. Alder L., Heath D. Lower oesophagus lined with intestinal and gastric epithelia. Thorax 1965, 20:66-72.
2. Hawe A., Payne W.S., Weiland L.H., et al. Adenocarcinoma in the columnar epithelial lined lower (Barrett) oesophagus. Thorax 1973, 28:511-514.
3. Haggitt R.C., Tryzelaar J., Ellis F.H., et al. Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus. American Journal of Clinical Pathology 1978, 70:1-5.
4. Haggitt R.C., Dean P.J. Adenocarcinoma in Barrett's epithelium. Barrett's esophagus: pathophysiology, diagnosis and management 1985, 153-166. Elsevier Science Publishing, New York. S.J. Spechler, R.K. Goyal (Eds.).
5. Murray L., Watson P., Johnston B., et al. Risk of adenocarcinoma in Barrett's oesophagus: population-based study. British Medical Journal 2003, 327:534-535.
6. Chandrasoma P., Wijetunge S., DeMeester S., et al. Columnar-lined esophagus without intestinal metaplasia has no proven risk of adenocarcinoma. American Journal of Surgical Pathology 2012, 36:1-7.
7. Harrison R., Perry I., Haddadin W., et al. Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. American Journal of Gastroenterology 2007, 102:1154-1161.
8. Chandrasoma P.T., Der R., Dalton P., et al. Distribution and significance of epithelial types in columnar-lined esophagus. American Journal of Surgical Pathology 2001, 25:1188-1193.
9. Gatenby P.A., Ramus J.R., Caygill C.P., et al. Relevance of the detection of intestinal metaplasia in non-dysplastic columnar-lined oesophagus. Scandinavian Journal of Gastroenterology 2008, 43:524-530.
10. Takubo K., Aida J., Naomoto Y., et al. Cardiac rather than intestinal type background in endoscopic mucosal resection specimens of minute Barrett adenocarcinoma. Human Pathology 2009, 40:65-74.
11. Liu W., Hahn H., Odze R.D., et al. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. American Journal of Gastroenterology 2009, 104:816-824.
12. Levine D.S., Blount P.L., Rudolph R.E., et al. Safety of a systematic endoscopic biopsy protocol in patients with Barrett's esophagus. American Journal of Gastroenterology 2000, 95:1152-1157.
13. Bennett C., Vakil N., Bergman J., et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 2012, 143:336-346.
14. Kaye P.V., Haider S.A., Ilyas M., et al. Barrett's dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry. Histopathology 2009, 54:699-712.
15. Villanacci V., Rossi E., Grisanti S., et al. Targeted therapy with trastuzumab in dysplasia and adenocarcinoma arising in Barrett's esophagus: a translational approach. Minerva Gastroenterologica e Dietologica 2008, 54:347-353.
16. Rossi E., Villanacci V., Bassotti G., et al. TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma. Histopathology 2010, 57:81-89.
17. Cestari R., Villanacci V., Rossi E., et al. Fluorescence in situ hybridization to evaluate dysplasia in Barrett's esophagus: a pilot study. Cancer Letters 2007, 251:278-287.
18. Villanacci V., Bellone G., Battaglia E., et al. Ski/SnoN expression in the sequence metaplasia-dysplasia-adenocarcinoma of Barrett's esophagus. Human Pathology 2008, 39:403-409.
19. Rossi E., Grisanti S., Villanacci V., et al. HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study. Journal of Cellular and Molecular Medicine 2009, 13:3826-3833.